When combining biomarkers according to the NIA-AA criteria [1] into a CSF-AD biomarker profile (i.e., reduced Aβ42 or Aβ42/Aβ40 ratio in combination with increased p-Tau concentration), concordance was 90%. The gene discussed is MAPT; the disease is Alzheimer disease.